Boston Scientific Reveals 2025 Q4 and Annual Results
Boston Scientific Corporation has reported robust financial results for the fourth quarter and the full year 2025, highlighting the company’s growth and innovation in the medical technology sector.
Q4 2025 Financial Highlights
For the fourth quarter of 2025, Boston Scientific achieved net sales of $5.286 billion. This represents:
- 15.9% growth on a reported basis
- 14.3% growth on an operational basis
- 12.7% growth on an organic basis
Net income attributable to shareholders was $672 million, or $0.45 per share, compared to $566 million, or $0.38 per share, for the same period last year. The adjusted earnings per share (EPS) increased to $0.80, up from $0.70 in the prior year.
Annual Results for 2025
Boston Scientific reported total net sales of $20.074 billion for 2025, showing a year-over-year growth of:
- 19.9% on a reported basis
- 19.2% on an operational basis
- 15.8% on an organic basis
Net income for the full year was $2.898 billion, or $1.94 per share, compared to $1.853 billion, or $1.25 per share, in 2024. The adjusted EPS increased to $3.06, up from $2.51 a year prior.
Segment Performance
Boston Scientific observed notable sales growth in various segments:
- Endoscopy: Sales increased to $760 million, a 10.1% growth
- Urology: Achieved $717 million in sales, up 13.8%
- MedSurg: Saw growth of 11.7%, reaching $1.809 billion
- Cardiovascular: Grew by 18.2%, totaling $3.477 billion
Regional Performance
Sales growth varied across regions:
- United States: 17.0% increase
- Europe, Middle East, and Africa (EMEA): 12.4% increase
- Asia-Pacific (APAC): 15.2% increase
- Latin America and Canada (LACA): 15.9% increase
- Emerging Markets: 15.4% increase
Innovations and FDA Approvals
In 2025, Boston Scientific made significant advancements, including:
- FDA approval for the FARAPOINT
Pulsed Field Ablation Catheter - Initiation of the OPTIMIZE clinical trial with the Cortex OPTIMAP technology
- Launch of the SEISMIQ Intravascular Lithotripsy System
- Introduction of new devices to enhance access and treatment in neuromodulation and cardiovascular procedures
2026 Outlook
Looking ahead, Boston Scientific anticipates continued growth, estimating net sales for 2026 to increase by approximately 10.5% to 11.5% on a reported basis. The adjusted EPS is expected to range from $3.43 to $3.49. For the first quarter of 2026, the company projects net sales growth of about 10.5% to 12.0% compared to the previous year.
Chairman and CEO Mike Mahoney stated that 2025 was an exceptional year, driven by innovation and high performance from their global teams, setting a solid foundation for future growth.
